KMAP BULLETIN: Preferred Drug List Update

Date: 03/22/24

There is a Preferred Drug List (PDL) update effective March 1, 2024. Reference the Preferred Drug List page on the Kansas Department of Health and Environment (KDHE) website.

Effective on and after March 1, 2024, PDL Prior Authorization (PA) is required for the following medications:

Adalimumab-afzb (Abrilada) Vial/Pen/Syringe
Adalimumab-atto (Amjevita) (Labeler 72511) Autoinjector/PFS
Adalimumab-adbm (Cyltezo®) (Brand Only) Pen/PFS
Adalimumab-fkjp (Hulio®) Pen/PFS
Adalimumab-adaz (Hyrimoz®) Pen/PFS
Adalimumab-aacf (Idacio®) (Brand Only) Pen/PFS
Adalimumab-aaty (Yuflyma®) Pen/PFS
Bimekizumab-bkzx (Bimzelx®) Pen/Syringe
Clindamycin/benzoyl peroxide/adapalene (Cabtreo) Gel
Cyclosporine (Vevye®) Ophth Solution
Etrasimod (Velsipity®) Tablet
Lovotibeglogene autotemcel (Lyfgenia®) IV bag
Methotrexate (Rasuvo®) Pen
Mirikizumab-mrkz (Omvoh®) Vial/Pen
Polyethylene glycol (PEG) ELS (Suflave) Oral solution
Secukinumab (Cosentyx®) Vial

Effective on and after March 1, 2024, the following medications are now PDL Preferred:

Adalimumab-aacf Pen
Adalimumab-adbm Pen/PFS
Exagamglogene autotemcel (Casgevy) IV bag
Vedolizumab (Entyvio®) Pen
Generic Methotrexate sodium injection Vial
Nalmefene (Opvee®) Nasal Spray

Note: The effective date of the policy is March 1, 2024. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.